Brought to you by 
Lorem gets rights to Cytori's cell therapy; deal terminated
08 Dec 2021
Executive Summary
Cardiovascular regenerative therapy-focused Lorem Vascular Co. Ltd. received a 30-year exclusive license to use regenerative medicine company Cytori Therapeutics Inc.’s cell therapy for all indications, excluding cosmetic and alopecia (hair loss) purposes. Lorem's initial focus will be on the treatment of diabetes and various renal and cardiovascular conditions. The company will hold rights in Hong Kong, Singapore, and Australia, with a 2014 launch planned in China and Malaysia.
Deal Industry
- Medical Devices
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Equity
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Lorem gets rights to Cytori's cell therapy; deal terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice